Publications by Mads Haugland Haugen

27 publications found

Publications 2021

  1. Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O (2021)
    Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
    JCO Precis Oncol, 5
    DOI 10.1200/PO.20.00086, PubMed 34036235
  2. Normann LS, Aure MR, Leivonen SK, Haugen MH, Hongisto V, Kristensen VN, Mælandsmo GM, Sahlberg KK (2021)
    MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
    Sci Rep, 11 (1), 10893
    DOI 10.1038/s41598-021-90385-2, PubMed 34035375

Publications 2020

  1. Halvorsen AR, Haugen MH, Öjlert ÅK, Lund-Iversen M, Jørgensen L, Solberg S, Mælandsmo GM, Brustugun OT, Helland Å (2020)
    Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
    Front Oncol, 10, 590755
    DOI 10.3389/fonc.2020.590755, PubMed 33324562
  2. Lien VT, Kristiansen MK, Pettersen S, Haugen MH, Krauss S, Olberg DE, Waaler J, Klaveness J (2020)
    Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation (vol 9, pg 37092, 2019)
    RSC Adv., 10 (9), 4927
    DOI 10.1039/d0ra90007a

Publications 2019

  1. Flem-Karlsen K, McFadden E, Omar N, Haugen MH, Øy GF, Ryder T, Gullestad HP, Hermann R, Mælandsmo GM, Flørenes VA (2019)
    Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
    Mol Cancer Ther, 19 (3), 895-905
    DOI 10.1158/1535-7163.MCT-19-0290, PubMed 31871265
  2. Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
    Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
    Breast Cancer Res, 21 (1), 61
    DOI 10.1186/s13058-019-1141-0, PubMed 31088535
  3. Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
    Breast cancer quantitative proteome and proteogenomic landscape
    Nat Commun, 10 (1), 1600
    DOI 10.1038/s41467-019-09018-y, PubMed 30962452
  4. Lien VT, Kristiansen MK, Pettersen S, Haugen MH, Olberg DE, Waaler J, Klaveness J (2019)
    Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation
    RSC Adv., 9 (63), 37092-37100
    DOI 10.1039/c9ra08954c
  5. Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
    Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
    Arch Pharm (Weinheim), 352 (9), e1900101
    DOI 10.1002/ardp.201900101, PubMed 31414521
  6. Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
    miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
    Mol Oncol, 13 (10), 2278-2296
    DOI 10.1002/1878-0261.12561, PubMed 31402562

Publications 2018

  1. Prasmickaite L, Tenstad EM, Pettersen S, Jabeen S, Egeland EV, Nord S, Pandya A, Haugen MH, Kristensen VN, Børresen-Dale AL, Oslo Breast Cancer Research Consortium (OSBREAC), Engebråten O, Maelandsmo GM (2018)
    Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4
    Mol Oncol, 12 (9), 1540-1558
    DOI 10.1002/1878-0261.12319, PubMed 29741811
  2. Seip K, Jørgensen K, Haselager MV, Albrecht M, Haugen MH, Egeland EV, Lucarelli P, Engebraaten O, Sauter T, Mælandsmo GM, Prasmickaite L (2018)
    Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment
    Cancer Lett, 439, 1-13
    DOI 10.1016/j.canlet.2018.09.023, PubMed 30240588

Publications 2017

  1. Lunde NN, Haugen MH, Bodin Larsen KB, Damgaard I, Pettersen SJ, Kasem R, Rut W, Drag M, Poreba M, Johansen HT, Solberg R (2017)
    Glycosylation is important for legumain localization and processing to active forms but not for cystatin E/M inhibitory functions
    Biochimie, 139, 27-37
    DOI 10.1016/j.biochi.2017.05.009, PubMed 28528272

Publications 2016

  1. Dahl JA, Jung I, Aanes H, Greggains GD, Manaf A, Lerdrup M, Li G, Kuan S, Li B, Lee AY, Preissl S, Jermstad I, Haugen MH, Suganthan R, Bjørås M, Hansen K, Dalen KT, Fedorcsak P, Ren B, Klungland A (2016)
    Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition
    Nature, 537 (7621), 548-552
    DOI 10.1038/nature19360, PubMed 27626377
  2. Hetland G, Eide DM, Tangen JM, Haugen MH, Mirlashari MR, Paulsen JE (2016)
    The Agaricus blazei-Based Mushroom Extract, Andosan™, Protects against Intestinal Tumorigenesis in the A/J Min/+ Mouse
    PLoS One, 11 (12), e0167754
    DOI 10.1371/journal.pone.0167754, PubMed 28002446
  3. Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L (2016)
    Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
    Oncotarget, 7 (15), 19997-20015
    DOI 10.18632/oncotarget.7671, PubMed 26918352

Publications 2015

  1. Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM (2015)
    Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
    Clin Exp Metastasis, 32 (8), 755-67
    DOI 10.1007/s10585-015-9742-1, PubMed 26349943
  2. Tamhane T, Lllukkumbura R, Lu S, Maelandsmo GM, Haugen MH, Brix K (2015)
    Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells
    Biochimie, 122, 208-18
    DOI 10.1016/j.biochi.2015.09.003, PubMed 26343556
  3. Tamhane T, Wolters BK, Illukkumbura R, Maelandsmo GM, Haugen MH, Brix K (2015)
    Construction of a plasmid coding for green fluorescent protein tagged cathepsin L and data on expression in colorectal carcinoma cells
    Data Brief, 5, 468-75
    DOI 10.1016/j.dib.2015.09.022, PubMed 26594658

Publications 2014

  1. Brix K, McInnes J, Al-Hashimi A, Rehders M, Tamhane T, Haugen MH (2014)
    Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges
    Protoplasma, 252 (3), 755-74
    DOI 10.1007/s00709-014-0730-0, PubMed 25398648
  2. Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K (2014)
    High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
    Eur J Cancer, 51 (1), 9-17
    DOI 10.1016/j.ejca.2014.10.020, PubMed 25466510

Publications 2013

  1. Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM (2013)
    Nuclear legumain activity in colorectal cancer
    PLoS One, 8 (1), e52980
    DOI 10.1371/journal.pone.0052980, PubMed 23326369

Publications 2012

  1. Smith R, Johansen HT, Nilsen H, Haugen MH, Pettersen SJ, Mælandsmo GM, Abrahamson M, Solberg R (2012)
    Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M
    Biochimie, 94 (12), 2590-9
    DOI 10.1016/j.biochi.2012.07.026, PubMed 22902879

Publications 2010

  1. Berge G, Andersen K, Haugen MH, Maelandsmo GM (2010)
    Comment on the Importance of S100A4 in regulation of MMP-13
    J Biol Chem, 285 (53), le23; author reply le24
    DOI 10.1074/jbc.L110.125898, PubMed 21186294
  2. Briggs JJ, Haugen MH, Johansen HT, Riker AI, Abrahamson M, Fodstad Ø, Maelandsmo GM, Solberg R (2010)
    Cystatin E/M suppresses legumain activity and invasion of human melanoma
    BMC Cancer, 10, 17
    DOI 10.1186/1471-2407-10-17, PubMed 20074384
  3. Paus E, Haugen MH, Olsen KH, Flatmark K, Maelandsmo GM, Nilsson O, Röijer E, Lundin M, Fermér C, Samsonova M, Lebedin Y, Stigbrand T (2010)
    TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins
    Tumour Biol, 32 (1), 1-12
    DOI 10.1007/s13277-010-0073-1, PubMed 20652782

Publications 2008

  1. Haugen MH, Flatmark K, Mikalsen SO, Malandsmo GM (2008)
    The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications
    BMC Cancer, 8, 172
    DOI 10.1186/1471-2407-8-172, PubMed 18554396

 
Page visits: 337